Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

168962

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, what the (a) membership and (b) terms of reference of the pneumococcal sub-committee of the Joint Committee on Vaccination and Immunisation will be.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217920
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217918 217919 question first answered 16/12/2014 17:17:39 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

168963

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, what opportunities there will be for external stakeholders to contribute to the Joint Committee on Vaccination and Immunisation's review of adult pneumococcal vaccination.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217919
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217918 217920 question first answered 16/12/2014 17:17:38 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

168964

registered interest
date	09/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the contribution by the Parliamentary Under-Secretary of State for Quality on 3 November 2014, House of Lords Official Report, column 1422, whether the recommendations made by the pneumococcal disease sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI) will be adopted by the JCVI upon completion of the sub-committee's work.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	217918
answer	answer is ministerial correction date of answer 16/12/2014 answer text <p>The advice of Joint Committee on Vaccination and Immunisation (JCVI) Sub-committees is considered by the JCVI, often alongside key evidence on which the advice is based. Following consideration of the evidence, the JCVI will make a decision on adoption of the Sub-committee’s advice.</p><p> </p><p> </p><p> </p><p>The JCVI review of the adult pneumococcal vaccination programme will begin in spring 2015, with a review of the relevant evidence being undertaken by a JCVI Pneumococcal Sub-committee. As set out in the JCVI Code of Practice, the JCVI will consider the advice of the Sub-committee and may decide to issue an interim statement for a short period of consultation with those stakeholders who submitted evidence that informed the Committee’s advice.</p><p> </p><p> </p><p> </p><p>The role of JCVI Sub-committees and the mechanism for selection of Sub-committee membership is described in the JCVI Code of Practice. The membership of established sub-committees is set out in minutes of the meetings and on the GOV.UK web site at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation" target="_blank">https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation</a>.</p><p> </p><p> </p><p> </p><p>Draft terms of reference for the JCVI Pneumococcal Sub-committee will be considered and agreed at the first meeting of the sub-committee and recorded in the minute of the meeting.</p><p> </p><p> </p><p> </p><p>The JCVI Code of Practice is available at:</p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224864/JCVI_Code_of_Practice_revision_2013_-_final.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 217919 217920 question first answered 16/12/2014 17:17:38 answering member 3918 label Biography information for Jane Ellison
tabling member	44 label Biography information for Sir David Amess

164378

registered interest
date	24/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 11 November 2014 to Question 213785, what the terms of reference are for the Pneumococcal sub-committee's review; if he will place in the Library a copy of the terms of reference of that review; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	215649
answer	answer is ministerial correction date of answer 27/11/2014 answer text <p>The terms of reference for the pneumococcal subcommittee of the Joint Committee on Vaccination and Immunisation (JCVI) will be agreed at its first meeting, to be held in spring 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>Once agreed, the terms of reference will be published in the minutes of the sub-committee meeting and available for public access on the gov.uk website.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 27/11/2014 17:27:30 answering member 3918 label Biography information for Jane Ellison
tabling member	46 label Biography information for Sir Simon Burns

155924

registered interest
date	17/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 11 November 2014 to Question 213785, under what circumstances additional modelling would be required by the pneumococcal disease sub-committee of the Joint Committee on Vaccination and Immunisation.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	214740
answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>Modelling conducted by Public Health England (PHE) will use information that includes the latest epidemiological data on pneumococcal disease in the United Kingdom. PHE will report its findings to the Pneumococcal Sub-committee. In addition to reports received from PHE, the Sub-committee will consider information including, but not limited to, reports provided by vaccine manufacturers. The Pneumococcal Sub-committee may request revised or additional modelling if the additional evidence considered suggests that there might be a substantial impact on the results of the original modelling conducted by PHE.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 24/11/2014 17:32:05 answering member 3918 label Biography information for Jane Ellison
tabling member	1604 label Biography information for Mr Virendra Sharma

155932

registered interest
date	17/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 11 November 2014 to Question 213785, whether the cost effectiveness modelling of the PPV programme developed by Public Health England will be made publicly available when it is presented to the pneumococcal disease sub-committee of the Joint Committee on Vaccination and Immunisation in spring 2015.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	214741
answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) Pneumococcal Sub-committee will meet in spring 2015. At this meeting of the Pneumococcal Sub-committee members will begin their review of the impact and cost-effectiveness of the pneumococcal polysaccharide vaccine (PPV) immunisation programme.</p><p> </p><p> </p><p> </p><p>The mechanism by which the JCVI undertakes economic evaluations, including cost-effectiveness analyses, are described in the JCVI Codes of Practice. The JCVI may, when appropriate, publish additional information on parameters used in cost-effectiveness models in the minutes of Sub-Committee and main JCVI meetings. This applies particularly to parameters for which there may be a substantial degree of uncertainty. The JCVI does not make public details of cost-effectiveness modelling where this would compromise the Department of Health's vaccine procurement process or disclose information provided in confidence to the JCVI by vaccine manufacturers. Additional modelling information is likely to be made publicly available through peer-reviewed publications.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 24/11/2014 17:30:49 answering member 3918 label Biography information for Jane Ellison
tabling member	1604 label Biography information for Mr Virendra Sharma

142209

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to paragraph 54 of the minutes of the meeting of 4 June 2014 of the Joint Committee on Vaccination and Immunisation, over what period of time Public Health England intends to revise the cost effectiveness model of pneumococcal polysaccharide vaccine to include the latest epidemiological data on pneumococcal disease in the UK; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	213785
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>Public Health England (PHE) will review modelling undertaken on the impact and cost-effectiveness of the Pneumococcal Polysaccharide Vaccine (PPV) programme in over-65 year olds using the latest epidemiological data on invasive pneumococcal disease in the United Kingdom. PHE will report its findings to the Pneumococcal Sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI). It is anticipated that the Pneumococcal Sub-committee will meet for the first time in spring 2015.</p><p> </p><p> </p><p> </p><p>At this meeting of the Pneumococcal Sub-committee members will review information including epidemiological data and PHE’s report on PPV impact and cost-effectiveness. Should all the required data be available to the Sub-committee, and subject to the requirement for additional meetings and, if required, additional modelling, it is anticipated that it will report to the JCVI main committee. The JCVI will form advice at the October 2015 meeting. The minutes of this meeting will be published in winter 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 15:48:49 answering member 3918 label Biography information for Jane Ellison
tabling member	46 label Biography information for Sir Simon Burns

142229

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to paragraph 49 of the minutes of the meeting of 4 June 2014 of the Joint Committee on Vaccination and Immunisation (JCVI), when his Department indicated to the JCVI that it would like the JCVI to confirm or revise its conclusions regarding the pneumococcal conjugate vaccine of choice for the UK; how his Department indicated its wish to the JCVI; whether he is satisfied that the JCVI has complied with his Department's request; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	213728
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>The request from the Department to the Joint Committee on Vaccination and Immunisation (JCVI) regarding the use of pneumococcal conjugate vaccine (PCV) in the United Kingdom was conveyed by Departmental officials via the JCVI secretariat within Public Health England in early 2014.</p><p> </p><p> </p><p> </p><p>At its meeting on 4 June 2014, the minutes of which are available on GOV.UK, the JCVI concluded that PCV13 should remain the pneumococcal conjugate vaccine of choice for the United Kingdom at this time. We have accepted this advice.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 15:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	46 label Biography information for Sir Simon Burns

61044

registered interest
date	10/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the availability of pneumococcal vaccine to (a) children, (b) adults under the age of 65 in at-risk groups and (c) adults over the age of 65; and if he will make a statement.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	199986
answer	answer is ministerial correction date of answer 17/06/2014 answer text <p>The objective of the immunisation programme against pneumococcal infection is to protect individuals for whom such infection is likely to be more common and/or serious. The following groups are eligible for vaccination under the national immunisation programme:</p><p> </p><p>- infants as part of the routine childhood immunisation programme;</p><p>- those aged 65 years or over; and</p><p>- children and adults in the clinical risk groups.</p><p>We are not aware of any supply problems with pneumococcal vaccines.</p><p><strong> </strong></p><p>The levels of uptake of pneumococcal vaccines are high. Latest uptake figures show that 94.4% of children in England had completed a primary immunisation course of pneumococcal conjugate vaccine at 12 months of age in 2012-13. This compares with 94.2% in 2011-12. Corresponding figures in adults aged 65 years or over for pneumococcal polysaccharide vaccine was 69.1% in 2012-13 compared to 68.3% in 2011-12.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/06/2014 16:14:17 answering member 3918 label Biography information for Jane Ellison
tabling member	104 label Biography information for Crispin Blunt

61050

registered interest
date	10/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons the Statement of Financial Entitlements for the pneumococcal vaccination Directed Enhanced Service for aged 65 years and over and for at-risk groups does not include a national payment scheme.
tabling member constituency	Reigate
tabling member printed	Crispin Blunt
uin	199985
answer	answer is ministerial correction date of answer 17/06/2014 answer text <p>The Directed Enhanced Service requires NHS England to establish a programme of pneumococcal vaccination for persons aged 65 years and over and to enter into arrangements with any primary medical services provider. It is for NHS England to determine the payments for this service. NHS England has agreed a national payment of £7.64 per dose for General Medical Services and Personal Medical Services providers for delivering the programme. The national specification is currently being finalised and will be published in due course.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/06/2014 16:02:10 answering member 3918 label Biography information for Jane Ellison
tabling member	104 label Biography information for Crispin Blunt